GI-108 for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Apr 2025: Trial started, NCT07172802
  2. 15 Sep 2025: Trial registered, NCT07172802

The trials

NCT07172802: A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
102 planned
Started
22 Apr 2025
Primary completion
Feb 2027
Arms
GI-108
Results
None posted
  1. 22 Apr 2025: Trial started
  2. 15 Sep 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.